• The company reported revenues of $589,000 for 2016
• Mergers and acquisitions have enabled AppSwarm to enter the e-commerce, health and education segments
• In-house software development has produced virtual reality products and expanded the app incubation/acceleration program

AppSwarm (OTC: SWRM), a publicly traded technology development and incubation acceleration firm, has experienced a momentum in 2017 that has boosted its ability to acquire applications for any device type. Reaching out to young application developers and entrepreneurs has paid off. The royalty agreements, joint ventures, stock purchase agreements, partnerships, and purchases have expanded the company’s financial resources, while mergers and acquisitions have bolstered software development as well. “The Swarm,” a selective screening process, enables the company to review app ideas and decide which projects to pursue.

Aside from reporting $589,000 in revenues for 2016, the company also reduced its corporate debt. In 2017, it has so far expanded its reach into the e-commerce, health and education markets and grown its in-house software development platforms. These, and the company’s application incubation/acceleration program, have enabled the development of virtual reality products and innovative new software.

Recent acquisitions include that of “Soccers,” acquired from TGTStudios; the game features block-style players and notable soccer teams. Tournaments range in difficulty and consider speed, defense, shooting ability, team morale, and other skill sets. “Komandir,” a virtual reality game, was recently acquired as well, from a prominent Russian development company, while “Avenging Soldiers” from developer Freak X Apps was recently launched. Also, AppSwarm recently launched its own game in the Apple App Store and Google Play Store – “Dead Uncleansed,” a tower defense style mobile game. “Turtles, Huh?” has a main game and various mini games in which players can complete 88 missions as the Turtle or the Penguin. Developed by Turtle Fly, it is designed for iOS platforms.

However, AppSwarm’s recent stream of acquisitions is not limited to games. A PDF document scanner app from TECHNOSYS was recently announced. It uses mobile device cameras to save images of PDF documents, with zoom and color/grayscale/black and white functions.

In addition to reaching into the estimated $7.2 billion virtual reality market, as calculated by Greenlight Insights’ Virtual Reality Industry Report: Spring 2017, AppSwarm has been focused on its in-house and acquired e-commerce development projects. Its compatibility with the company’s incubation system led to the acquisition of Urban Bamboo Designs, launching its website and focusing on the eco-friendliness of the material in many forms of products. Bamboo is strong, lightweight, and flexible, as well as affordable. As such, underdeveloped economies often benefit from its purchase. AppSwarm also stands to benefit from the e-commerce site selling eco-friendly watches, bracelets, sunglasses, phone cases, and décor.

In the first half of 2017, the company has built momentum through mobile app development and acquisitions while expanding its marketing services. Thanks to a lean corporate expenditure profile and profit-based incentive compensation, its strategy continues to be successful.

For more information, visit the company’s website at www.App-Swarm.com

Let us hear your thoughts: AppSwarm, Inc. Message Board

• Proprietary biosynthesis process to produce cannabinoids
• Cannabinoid bioinformatics system that identifies optimal R&D pathways
• Lead candidate targeting billion dollar market

Despite the awe-inspiring shadow cast by the moon on August 21, 2017, there’s no eclipse in sight for InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF). The Vancouver, Canada-based company continues its research and development (R&D) into the therapeutic benefits of cannabinoids, an activity that holds the promise of exceedingly rich reward. Peer valuations have skyrocketed, increasing the likelihood that unicorns may soon appear on the cannabis biotech landscape. With a triad of valuable core assets, it won’t be surprising if, sometime in the future, InMed turns out to be one of them.

InMed Pharmaceuticals has more to offer than the typical drug discovery and development company. Its triple play comprises a proprietary technology based on biosynthesis, a bioinformatics system, and a robust drug development pipeline, any one of which may propel this innovative biotech to success. The company has developed a process to manufacture cannabinoids by applying cannabinoid DNA to Escherichia-coli (E. coli) bacteria. The E. coli DNA is then removed, leaving just the cannabinoid DNA, which can then replicate in a process known as biosynthesis. Biosynthesis is widely employed in the pharmaceutical industry and is used, for example, to manufacture the insulin upon which millions of diabetics rely.

InMed’s bioinformatics system, employing proprietary algorithms, identifies the cannabinoids most likely to have beneficial therapeutic effect in serious diseases with high unmet medical needs. The program integrates data from numerous bioinformatics databases, including a database on the structure of currently approved pharmaceutical products and an extensive proprietary database of over 90 individual cannabinoid drugs found in cannabis. This bioinformatics tool has already identified several therapies, including the company’s two lead pipeline candidates, INM-750 and INM-085.

INM-750 is for the treatment of a rare genetic connective tissue disorder called epidermolysis bullosa (EB). EB is an orphan pediatric disease characterized by extremely fragile skin that affects roughly one out of every 20,000 births in the United States. The condition, which currently has no approved treatment or cure, has been called “The Worst Disease You’ve Never Heard Of” by the Dystrophic Epidermolysis Bullosa Research Association of America. INM-750 works by replacing missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB. It has potential global market revenues of approximately $1 billion.

INM-085 targets glaucoma, a leading cause of blindness, according to the Glaucoma Research Foundation. The drug reduces the elevated intra-ocular pressure that is often associated with glaucoma and so holds the promise of providing relief to the more than three million Americans who currently have glaucoma.

Both INM-750 and INM-085 are in the pre-clinical phase, and InMed is taking the lead with the former, which it is hoping to advance to phase I clinical trials in 2018. If all goes well, INM-750 is expected to be in phase III by 2020, setting InMed on a trajectory, if peer comparisons are any indication, to a much higher valuation than its current one of under $50 million. Scioderm, for example, was acquired by Amicus two years ago for $847 million. This acquisition was based on the results of a phase II study of its sole clinical asset Zorblisa, which involved only 42 patients. Zorblisa, for the treatment of EB, is currently in phase III.

InMed’s pipeline is in good hands. Its chief scientific officer is Dr. Sazzad Hossein, who brings more than 20 years of academic and industrial experience in new drug discovery and natural health product development to the C-suite. He was, at one time, group leader and senior scientist at Biotechnology Research Institute of National Research Council Canada, the Government of Canada’s prime biotechnology research organization, where he set up a pharmacology laboratory to evaluate the safety and efficacy of new drugs under development in the areas of cancer and cardiovascular and ocular diseases. He is also the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.

InMed’s chief medical officer is Dr. Ado Muhammed. Muhammed joined the company from GW Pharmaceuticals, developer of Sativex, where he was associate medical director, distinguishing InMed as the only biopharmaceutical company in North America with a senior GW team member on its executive team.

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board

• Moxian praised for new joint venture strategy to help penetrate key markets in China
• Crystal Equity Research projects Moxian’s sales reaching $2.3 million in FY2018
• Moxian adding three to its board of directors, including Liu Shu Juan, CEO of Shewn International Group, Inc.

Moxian, Inc.’s (NASDAQ: MOXC) price target of $5.25 remains unchanged in the August 15, 2017, update report from Crystal Equity Research LLC (http://dtn.fm/hmV0h), which published its initial report on the company in January 2017. Crystal classified an investment in the company as a ‘speculative buy’ and made positive note of the firm’s joint venture with Shewn International Group in Shanghai. It also said it anticipates revising its revenue estimates for Moxian upward when the Shewn transaction is formalized.

Moxian is an integrated platform operator in the midst of converting its unpaid platforms to paid. Its joint venture with upscale wine distributor Shewn — expected by Crystal Equity to be finalized by the end of September 2017 — calls for Shewn to use Moxian+ Merchant App technology. It uses a UnionPay module processing system and offers Moxian’s Mo-Points redemption plan. In return, Shewn offers Moxian quicker and less costly market penetration and an additional revenue stream. Moxian will earn a fee on Shewn’s digital sales processed on the Moxian+ platform.

“Execution on the Shewn International joint venture should put greater certainty into the Moxian story, providing the foundation for greater investor confidence and a higher valuation of the shares. We view it as an important catalyst for valuation. In our view, the stock provides an interesting play on China’s e-commerce industry” the report said.

Moxian has already signed a memorandum of understanding with Shewn. The research company quoted James Mengdong Tan, CEO of Moxian, as saying that he anticipates 30-40 more joint venture possibilities in the pipeline. Crystal Equity also liked Moxian’s lower cash usage in the quarter ended June 2017, resulting from reduced SG&A costs.

According to an 8K SEC filing on August 16, 2017 (http://dtn.fm/9ho1I), Moxian also had a change in its board of directors. It added Chan Fook Meng, Dr. Yu Lin and Liu Shu Juan to the board. Liu, currently the CEO of Shewn International Group, Inc., is also financial controller of Shanghai Shewn Wine Co. Ltd., the main operating company for Shewn in China. At Moxian, Liu will also serve as Moxian’s executive director.

For more information, visit the company’s website at www.Moxian.com

• Commencing volume manufacturing, allowing ramp-up of distribution and sales
• Partnering with Bitcoin Capital to create proprietary bitcoin payment solution to serve cannabis industry

SinglePoint, Inc. (OTC: SING) continues making great strides in its strategic diversification efforts and has become a compelling and diversified player within the cannabis market. In a recent article, SinglePoint was mentioned among other standout companies that are making their mark in unique ways within the cannabis industry (http://dtn.fm/7zM4s). Shining among these other standouts in the blossoming legal marijuana market, SinglePoint has begun demonstrating its ability to generate revenues through strategic acquisitions in the marijuana space—all without ever touching the plant.

Among its exciting achievements, SinglePoint recently forged an agreement with Premier Biomedical, Inc. (OTCQB: BIEI) to act as a volume supplier in the manufacture of Premier’s new CBD Hemp Oil Skin Patch, which is anticipated to be the first in a line of products stemming from the agreement between the two companies.

Commencing the volume manufacturing of its products will enable Premier to start aggressively expanding its distribution network and increase sales volumes in domestic and foreign markets. For SinglePoint, it is anticipated that this new business will significantly contribute to the company’s revenue goals.

SinglePoint has also been working diligently in its acquisition efforts and inside sales in order to bolster revenues. Among the company’s other recent accomplishments, SinglePoint has joined forces with First Bitcoin Capital Corp. (OTC: BITCF) to create a proprietary bitcoin payment solution to serve U.S. cannabis businesses that are currently “unbankable” due to federal restrictions. The bitcoin solution is being collaboratively developed by the two companies and can be deployed in any point-of-sale machine through a simple download. This will allow marijuana businesses to begin accepting credit and debit card purchases independent of banks and the FDIC, giving cannabis customers a seamless payment experience similar to what they would have in any type of store.

The bitcoin solution will further build on SinglePoint’s track record of offering advanced payment technologies. The company already serves the cannabis industry through its SingleSeed subsidiary (www.SingleSeed.com), which supplies various services to marijuana businesses and has become a hub for dispensaries that are looking for payment processing solutions and other business tools. SingleSeed additionally provides payment processing and text message marketing solutions for marijuana businesses.

Other SinglePoint endeavors include the company’s recent acquisition of Discount Indoor Garden Supply (DIGS), which has positioned the company to be a leader in online products, retail stores, cannabis consulting and equipment in California, serving the thousands of marijuana-related businesses in that state. SinglePoint has acquired 90 percent ownership of DIGS.

SinglePoint also invested in Convectium earlier this year. This California-based provider of equipment, branding and packaging solutions for the cannabis industry developed the very first cartridge and vape pen oil-filling machines offered for wholesale distribution to cannabis dispensaries. Convectium’s 710Shark and 710Seal machines, currently sold through the EquipCanna.com website, are able to fill and package over 100 cartridges of disposable vape pens in only 30 seconds. Additionally, Convectium operates a consumer brand that includes HazeSticks and BlackoutX products.

SinglePoint continues to stand out among companies that are making their mark in the marijuana space through distinctive approaches to this burgeoning market. With so many rivals now looking for a piece of the pie in the marijuana space, SinglePoint’s diversification and unique approaches to profiting from the cannabis boom without actually touching the plant make this company one to watch.

For more information, visit the company’s website at www.SinglePoint.com

Let us hear your thoughts: SinglePoint, Inc. Message Board

• Alzheimer’s is a leading cause of dementia in adults in the United States
• IGC’s cannabis-based drug may reverse the buildup of beta-amyloid plaque
• Hyalolex and other phytocannabinoid-based drugs are fueling potential for the company’s market valuation growth

Alzheimer’s disease is currently the sixth-leading cause of death in the nation and the most common cause of dementia in older individuals. The chronic neurodegenerative disease has had no cure or effective treatment for reducing its symptoms, but India Globalization Capital, Inc. (NYSE MKT: IGC) is seeking to change that with a potential blockbuster drug. Hyalolex, otherwise known as IGC-AD1, is a cannabis-based drug that has the potential to reduce beta-amyloid plaque buildup in the brain, with the possibility of lessening some of the symptoms of the disease. A recent article focused on the efforts of IGC and other pharmaceutical companies to develop cannabinoid-based therapies for a range of serious diseases can be found at http://dtn.fm/7OmXx.

In June 2017, the company announced its acquisition of exclusive rights, from the University of South Florida, for a tetrahydrocannabinol (THC)-based treatment. A study conducted at the university found that the cannabis extract reversed beta-amyloid accumulation in mice. Subsequently, IGC became the exclusive licensee of the patent “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” It involves a new pathway for low doses of the compound to bind to the plaque and prevent it from collecting on nerve cells (the process thought to result in cognitive decline).

Hyalolex isn’t the only pipeline drug driving the potential for IGC’s market valuation growth. Several cannabis companies have seen hundreds of millions, even billions, of dollars in market valuations with phytocannabinoid-based therapies. Plus, IGC isn’t limiting its drug development to novel Alzheimer’s treatments. Others include Serosapse, for Parkinson’s disease; Natrinol, to treat cachexia in AIDS and cancer patients; and Caesafin, a combination therapy that targets dogs and cats with seizures.

Currently, IGC is the only publicly-traded pharmaceutical cannabis stock that addresses Alzheimer’s disease. However, a number of studies suggest the therapeutic value of treating the disease with cannabis-based drugs. These include studies of how THC molecules can potentially bind to and break up amyloid-beta proteins and other analysis suggesting positive results and that patients for the most part tolerate the effects of THC. A study on mice, conducted in partnership between the University of Bonn and the Hebrew University of Jerusalem, found low-doses of cannabis improved the memory and increased nerve cell links in older subjects.

The treatment of Alzheimer’s is a lucrative market opportunity, and pharma companies operating in that space are experiencing significant valuations. Anavex Life Sciences, which currently has a candidate in a phase IIa clinical trial for Alzheimer’s disease, has a market cap of around $179 million.

For more information about India Globalization Capital and its groundbreaking phytocannabinoid therapies for Alzheimer’s and other diseases, visit www.IGCInc.us

• Avoids federal legal issues by sourcing hemp grown outside U.S. and focusing on federally legal cannabidiol (CBD)
• Targets rapidly developing cannabis market, with cannabidiol alone expected to reach over $2 billion by 2020
• Distribution already covers all 50 states, and is growing internationally

PotNetwork Holdings, Inc. (OTC: POTN), based in Fort Lauderdale, Florida, is a holding company. The company’s First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

• Diamond CBD Gummies – Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
• Chill Gummies – Chill gummies are more robust than its counterpart, the “Relax” gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
• CBD Liquid Gold – CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
• Blue CBD – Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
• Relax Gummies – Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that’s looking for a lighter effect without sacrificing quality or taste.
• Premium Hemp Liquid Pet – CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
• CBD Re-Leaf – Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
• Relax Extreme CBD – Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
• CBD Double Shot – CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it’s that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
• Chill Pill – CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions.

For more information, visit the company’s website at www.PotNetworkHolding.com

Let us hear your thoughts: PotNetwork Holdings, Inc. Message Board

• The precast concrete manufacturer, for the half ended the same date, recorded a 14.1% rise in revenues and a 377% spike in net income
• Safety barrier project in Northern Virginia has SMID working at full capacity seven days a week to meet deadlines
• Company has backlog of $30.2 million, optimistic about profitable performance in 2018

Smith-Midland Corporation (OTCQX: SMID), a precast concrete manufacturer, has announced (http://dtn.fm/Rr9pC) an 11.4% jump in sales for the quarter ended June 30, 2017, and a 69.9% increase in net income. Sales rose to $10.7 million for the quarter, compared to $9.6 million for the same period last year. In the most recent quarter, net income increased to $711,653, compared to $418,924 the same period in 2016.

For the six months ended June 30, 2017, the company generated revenues of $20.2 million, 14.1% higher than the $17.7 million during the same period a year ago. Net income rose to $1,568,854, a 377% jump from $329,148 during the same period the prior year. In its SEC 10-Q filing of August 10, 2017 (http://dtn.fm/XMP5g), the company attributed the gains to a lower cost of goods and increases in sales of high margin products.

Smith-Midland, based in Midland, Virginia, is a precast concrete company which specializes in producing, renting, licensing and selling products for the construction, utilities and transportation industries.

In a news release, Rodney Smith, chairman and chief executive officer, said, “Smith-Midland’s earnings continue to demonstrate our ability to generate profitable returns on a quarter by quarter basis. Lean process improvements and our commitment to customer satisfaction have helped drive quality performance to the bottom line results. With an increase in the current backlog to $30.2 million, the company is well positioned to continue its profitability in 2018.”

He added that Smith-Midland has a purchase order for the safety barrier on the I-395 high occupancy toll lane project in Northern Virginia, as a result the company is working seven days a week to meet the delivery dates required within the contract. He also noted that Smith-Midland is actively bidding for other large safety projects, as well as highway safety wall projects.

For more information, visit the company’s website at www.SmithMidland.com

• Industry leader projects cryptocurrency bitcoin, which has achieved $4,000 price, can reach $100,000 within five years
• Company provides processing solution for “unbankable” risk markets, such as legalized cannabis
• SinglePoint releases new investor relations kit that details its acquisition strategy, profiles key executives (http://dtn.fm/eZ4HE)

SinglePoint, Inc. (OTC: SING) finds itself at the intersection of two fast-growth markets: the cryptocurrency bitcoin and legalized cannabis. Bitcoin prices recently surged past $4,000 and are projected by industry leader Wu Jihan, founder of bitcoin miner Bitmain, to possibly reach $100,000 within five years, according to a video by Bloomberg L.P. (http://dtn.fm/9mHDH). At the same time, research from Cowen & Company estimates that legalized cannabis sales could reach $50 billion by 2026, according to a Bloomberg L.P. Markets report (http://dtn.fm/U5Nle).

SinglePoint is a high-technology company offering payment processing solutions in high risk markets, such as the legal cannabis industry. That market operates independently of conventional banks. In a joint venture with First Bitcoin Capital, Inc. (OTC: BITCF), SinglePoint uses its own proprietary technology to process transactions in bitcoins for the “unbankable” cannabis market. The company has also made acquisitions within the cannabis industry, including SingleSeed, Convectium and Discount Indoor Garden Supply (DIGS).

Cannnabis dispensaries are seeking a solution for customer transactions which are federally limited in their payment options, requiring payments independent of traditional banks and the FDIC. Bitcoin represents a payment option to dispensaries which are concerned about doing business in a cash-only environment. SinglePoint gives those dispensaries a bitcoin solution (http://dtn.fm/SeI4U). Further, SinglePoint’s acquisitions in the cannabis industry also reinforce its involvement within that fast growing business.

SinglePoint recently released a 16-page investor relations kit, which profiles key executives in the company, as well as detailing the firm’s marketing strategy, acquisitions and diversification into horizontal markets.

For more information, visit the company’s website at www.SinglePoint.com

Let us hear your thoughts: SinglePoint, Inc. Message Board

• Core operations transitioned to phytocannabinoid-based therapies
• Four trial candidates targeting chronic pain, Alzheimer’s and other conditions
• Unique approach combining existing therapies with cannabinoids

India Globalization Capital, Inc. (NYSE MKT: IGC) is developing disruptive new pharmaceutical therapies to fight a variety of ailments. Currently, the Maryland-based corporation has a pipeline of cannabis-based combination candidates under development to treat Alzheimer’s disease, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy. Supporting this effort, the company has put together a robust intellectual property (IP) portfolio. IGC intends nothing less than to become a leading specialty provider of phytocannabinoid-based pharmaceuticals and complimentary alternative medicine (CAM) nutraceutical products. Operating in the world’s fastest growing industry (cannabis) with its novel ‘something old, something new’ approach, IGC could soon expect its valuation to rise in line with peers like Corbus Pharmaceuticals (NASDAQ: CRBP), Anavex Life Sciences (NASDAQ: AVXL) and Zynerba Pharmaceuticals (NASDAQ: ZYNE).

IGC recently disposed of its low-margin iron ore and electronic trading businesses. With that divestment, the company is now focused on its long-term goal of becoming a heavyweight in the cannabis space. To achieve its objective of being a major player of cannabinoid combination therapies, IGC is actively engaged in planning the development pathways for its four product candidates.

IGC-501 heads IGC’s quartet of pipeline candidates. In September 2015, the company filed a Patent Cooperation Treaty (PCT) application for the therapy, which addresses neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. At present, such indications tend to be treated with opioids, which are notoriously addictive. However, the alarming rise and devastating effects of opioid abuse are driving the search for less pernicious alternatives. In the U.S. alone, this presents a market opportunity of around $25 billion.

A PCT filing has also been made for IGC-502, designed to treat canine seizures, which affect about five percent of dogs. Additionally, in August 2016, the company filed for a therapy to treat cachexia, which it has designated IGC-504. Also known as wasting syndrome, cachexia affects about 1.3 million in the U.S. It is a condition that’s typically associated with cancer, multiple sclerosis (MS), Parkinson’s, and HIV/AIDS.

In June 2017, IGC announced it had entered into a definitive agreement with the University of South Florida making IGC the exclusive licensee of the U.S. patent filing entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” This agreement gives IGC a way to enter a huge market for what has been called ‘America’s most expensive disease.’ For 2017, Medicare and Medicaid expenditures for treating Alzheimer’s are expected to reach $175 billion. Currently, over 5.3 million Americans suffer from the condition, and that number is expected to double over the next 20 years.

The drug candidate IGC-ADI explores an alternative way delta 9-tetrahydrocannabinol (THC) interacts with the human body. Several pathways have already been identified, including binding to the CB1 receptor, anti-oxidative effects, and others, but IGC-ADI works through a different molecular pathway that allows low doses of THC to bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which causes the cognitive decline that results in Alzheimer’s disease. If approved, this patent will give IGC a significant proprietary interest in a unique way to treat Alzheimer’s disease. THC is the psychotropic phytocannabinoid mainly responsible for the ‘high’ of cannabis, although, it must be noted, other cannabinoids such as cannabinol (CBN) and tetrahydrocannabivarin (THCV) are psychotropic. The treatment of Alzheimer’s is a lucrative market opportunity, and pharma companies operating in that space are experiencing significant valuations. Anavex Life Sciences, which currently has a candidate in a Phase IIa clinical trial for Alzheimer’s disease, has a market cap of around $179 million.

The same is true of companies developing cannabinoid-based treatments. Corbus Pharmaceuticals, which presently has programs assessing its oral endocannabinoid-mimetic drug candidate for treating a variety of ailments, has a current market cap of around $310 million, and Zynerba, which is also developing synthetic cannabinoids, has a market cap of about $235 million at present. IGC, trading presently at $0.40, has a market cap of about $12 million, a valuation that is unlikely to stay that low for long.

For more information, visit the company’s website at www.IGCInc.us

• Poised for rapid revenue development following acquisition of MediaPlay
• Agreements in place with leading application stores to fast-track applications
• Company had $589,000 in revenues in 2016 and was able to eliminate more than $500,000 in corporate debt

Technology development and incubation acceleration company AppSwarm, Inc. (OTC: SWRM) has announced its acquisition of MediaPlay, a multiplatform games publisher and developer (http://dtn.fm/QM3ia). The company has further announced the creation of two AppSwarm divisions.

Assets purchased as part of the acquisition include:

• Games in-house
• Rights to games currently in negotiations
• Pending letters of intent
• Pending distribution agreements
• Work-for-hire contracts

MediaPlay has a special focus on free-to-play mobile games and is led by a core team composed of veterans of the game industry who have made successful exits in previous ventures and have held executive positions with some of the world’s largest gaming companies, such as Electronic Arts, Kabam and Activision. Collectively, the MediaPlay team is responsible for the launch of more than seven companies.

Historically, MediaPlay’s team has created organic growth by developing some of its own products, as well as through third-party acquisitions of branded games. The MediaPlay team has had tremendous ongoing success and has had its games featured by Apple and Google multiple times. The team executed a three-game development and publishing agreement with Discovery Networks in 2016 and has made subsequent deals with Valiant Entertainment and other brands.

AppSwarm anticipates rapid revenue development within the next 24 months as a result of this acquisition. MediaPlay brings an acute focus on nurtured relationships and international contacts, as well as a proven ability to bring about major corporate developments and publishing agreements.

The acquisition further enables AppSwarm to form two distinct but synergistic gaming divisions and revenue streams. The company’s current efforts will be focused on the application Incubation and Acquisition Division, which includes gaming opportunities, interactive developments and e-commerce business solutions.

Focused on partnering with app developers, AppSwarm is engaged in accelerating the development of free-to-play mobile games and fast-tracking them to the market. The company partners with game developers through joint ventures, royalty agreements, marketing partnerships and outright purchases.

AppSwarm actively reaches out to budding, entrepreneurial-minded application developers with great ideas who lack the knowledge to effectively market their products. When the company identifies an application with potential, the person or firm that created the app is approached by AppSwarm for the purposes of negotiating a stock purchase agreement, royalty agreement, joint venture, partnership or outright purchase.

AppSwarm has enviable financial resources to help market applications in the most effective ways. The company uses all forms of social marketing, along with traditional marketing, to get an app before as many eyes as possible. AppSwarm further has agreements in place with the foremost application stores, enabling the company to fast-track its applications.

In 2016, AppSwarm had revenues of $589,000, and the company was able to eliminate well over $500,000 in corporate debt. This enabled AppSwarm to commence 2017 with the momentum to complete synergistic mergers and acquisitions, such as the acquisition of MediaPlay.

For more information, visit the company’s website at www.App-Swarm.com

Let us hear your thoughts: AppSwarm, Inc. Message Board